About Green Valley
Who we are

Green Valley is a Chinese pharmaceutical company with the courage to face up to toughest human health challenges with a high sense of responsibility. We are also known for innovative R&D within the Chinese pharmaceutical industry. We develop only the medicine that human beings most hope for, and bring about meaningful changes to people’s life.

What we are committed to

We are deep diving into the gut-brain axis study with a holistic view of treatment. Based on these findings, we are possible to uncover a new angle to interpret the pathogenesis of chronic and complex diseases. Those insights are expected to become a major driving force to help us address unmet medical needs.

Why we exist

We exist for the patients worldwide who are suffering from chronic and complex diseases.

Currently, the human disease spectrum is undergoing tremendous changes, and factors affecting human health have gone far beyond gene or cell. Only by means of returning to the very origin essence of life can we discover the fundamental solutions. For chronic and complex diseases including neuroscience, oncology, cardiovascular, metabolism and autoimmunity,  a single-target treatment strategy is inadequate to meet medical needs.. As a result, tens of thousands of patients affected are still in a predicament where there's no treatment for their diseases. Thus, we focus our efforts on carbohydrate drugs development to seek better choices for patients worldwide.

Founded in
2018
Headquartered in Zhangjiang Science City
A leader in carbohydrate drug R&D and manufacture
Green Valley Research Institute
Led by academicians
300+ Carbohydrate drug scientists

Focus areas

Neuropsychiatric diseases, oncology, cardiovascular diseases, metabolic diseases and autoimmune diseases

Employees
about1500
2 Carbohydrate drug manufacture sites
in Shanghai and Liaoning Province
Advanced Carbohydrate drug R&D technology platform and innovative product pipeline
Our History
2018
2019
2020
2021
2022

Green Valley (Shanghai) Pharmaceuticals Co., Ltd. was founded.

GV-971 was approved conditionally by NMPA on November.

GV-971 officially launched the Chinese market on December.

Green Valley officially kicked off construction on its carbohydrate drug manufacturing facility in Shanghai on July, which will be the first manufacturing site in China that supplies carbohydrate drugs globally.

GV-971 received approval by FDA on the IND application for a global multi-center Phase III clinical trial on April and kicked off patient-enrollment process on October.

Green Valley (Shanghai) Pharmaceuticals Co., Ltd. was authorized with pharmaceutical manufacturing license.

GV-971 Gets Included in China National Reimbursement Drug List.